Author:
Danilycheva I V,Shulzhenko A E,Bondarenko N G
Abstract
Omalizumab - monoclonal therapeutic antibody to human IgE, is effectively used for the treatment of patients with chronic spontaneous urticaria (HSC), refractory to 4 times increased doses of antihistamines. The article describes two cases of effective treatment of patients (HSC) with omalizumab (Xolair® «Novartis Pharma» LLC) after a long period of unsuccessful therapy with H1-antihistamines, leukotriene receptor antagonists, and corticosteroids.
Reference10 articles.
1. Федеральные клинические рекомендации по диагностике и лечению крапивницы. Российская ассоциация аллергологов и клинических иммунологов. Росс. Аллергол. Журн. 2011, № 1, с. 38-46.
2. Zuberbier Т., Aberer W., Asero R. EAACI/GA2LEN/EDF/ WAO urticaria guideline for the definition, classification, diagnosis, and management of urticaria:the 2013 revision and update. Allergy. 2014.
3. Maurer M., Weller K., Bindslev-Jensen C. et al. Unmet clinical needsin chronic spontaneous urticaria. A GA2LEN task force report. Allergy. 2011, v. 66, p. 317-330.
4. Martin Metz, Tatevik Ohanyan, Martin K. Church et al. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: A retrospective clinical analysis. Journal of Dermatological Science. 2014, v. 73, p. 57-62.
5. Saini S., Rosen K.E., Hsieh H.J. et al. A randomized, placebo-controlled, dose-ranging study of single-dose omalizumab in patients with H1-antihistamine-refractory chronic idiopathic urticaria. J. Allergy Clin. Immunol. 2011, v. 128, p. 567-573.